Quilaban provides new generation of automated testing for Mycobacterium tuberculosis infection detection

LIAISON® QuantiFERON®-TB Gold Plus II is a new version of the automated test for detecting latent tuberculosis infection, based on measuring the immune response to Mycobacterium tuberculosis, combining greater speed and processing capacity with validated clinical performance.

Quilaban strengthens its portfolio in the diagnostics field with the launch of LIAISON® QuantiFERON®-TB Gold Plus II, a high-performance automated test based on the IGRA (Interferon-Gamma Release Assay) methodology for detecting latent tuberculosis infection. This new version combines the technology of QuantiFERON®-TB Gold Plus collection tubes with an optimised workflow on DiaSorin’s LIAISON® XS and XL analysers.

The test is based on a chemiluminescence immunoassay (CLIA) that enables quantification of interferon-gamma (IFN-γ) released by T lymphocytes after stimulation with Mycobacterium tuberculosis-specific antigens. After incubation of whole blood samples in specific tubes, the LIAISON® system measures interferon-gamma (IFN-γ) in plasma, enabling objective and reproducible inference of Mycobacterium tuberculosis infection.

Among the main improvements, the increase in operational efficiency stands out, with the first result obtained in approximately 32 minutes and a processing capacity up to 75% higher, reaching 171 tests per hour. The optimised reagent design and the possibility of direct sample loading in less than one minute without the need for additional processing contribute to significantly simplifying laboratory workflow.

These characteristics enable laboratories to increase testing capacity or internalise latent tuberculosis infection diagnosis, reduce operational costs, shorten response time and consolidate diagnostics on automated LIAISON® family systems, promoting greater efficiency and productivity.

Maintaining the high performance standards of QuantiFERON®-TB Gold Plus, now discontinued, LIAISON® QuantiFERON®-TB Gold Plus II presents equivalent clinical sensitivity and specificity, ensuring reliable IGRA results without cross-reactivity in BCG-vaccinated individuals. Its performance has been validated in different populations, including patients with active tuberculosis and various risk groups.

With this new solution, Quilaban reinforces its commitment to providing innovative technologies that support healthcare professionals in improving diagnostics and optimising patient care.

QIAGEN products are in vitro diagnostic medical devices for professional use only. Consult the information on the packaging and instructions for use.